Literature DB >> 22076255

CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Michael R Sierks1, Gaurav Chatterjee, Claire McGraw, Srinath Kasturirangan, Philip Schulz, Shalini Prasad.   

Abstract

Protein misfolding and aggregation is a critically important feature in many devastating neurodegenerative diseases, therefore characterization of the CSF concentration profiles of selected key forms and morphologies of proteins involved in these diseases, including β-amyloid (Aβ) and α-synuclein (a-syn), can be an effective diagnostic assay for these diseases. CSF levels of tau and Aβ have been shown to have great promise as biomarkers for Alzheimer's disease. However since the onset and progression of many neurodegenerative diseases have been strongly correlated with the presence of soluble oligomeric aggregates of proteins including various Aβ and a-syn aggregate species, specific detection and quantification of levels of each of these different toxic protein species in CSF may provide a simple and accurate means to presymptomatically diagnose and distinguish between these diseases. Here we show that the presence of different protein morphologies in human CSF samples can be readily detected using highly selective morphology specific reagents in conjunction with a sensitive electronic biosensor. We further show that these morphology specific reagents can readily distinguish between post-mortem CSF samples from AD, PD and cognitively normal sources. These studies suggest that detection of specific oligomeric aggregate species holds great promise as sensitive biomarkers for neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076255      PMCID: PMC3334303          DOI: 10.1039/c1ib00018g

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  65 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

3.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

4.  Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

Authors:  L Narhi; S J Wood; S Steavenson; Y Jiang; G M Wu; D Anafi; S A Kaufman; F Martin; K Sitney; P Denis; J C Louis; J Wypych; A L Biere; M Citron
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

Review 5.  Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.

Authors:  William T Hu; Alice Chen-Plotkin; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Leo McCluskey; Lauren Elman; Jason Karlawish; Howard I Hurtig; Andrew Siderowf; Virginia M-Y Lee; Holly Soares; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2010-07-22       Impact factor: 17.088

6.  Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form.

Authors:  Srinath Kasturirangan; Lin Li; Sharareh Emadi; Shanta Boddapati; Philip Schulz; Michael R Sierks
Journal:  Neurobiol Aging       Date:  2010-11-09       Impact factor: 4.673

7.  Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease.

Authors:  Dimitra G Georganopoulou; Lei Chang; Jwa-Min Nam; C Shad Thaxton; Elliott J Mufson; William L Klein; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-04       Impact factor: 11.205

8.  Characterizing antibody specificity to different protein morphologies by AFM.

Authors:  Min S Wang; Andleeb Zameer; Sharareh Emadi; Michael R Sierks
Journal:  Langmuir       Date:  2009-01-20       Impact factor: 3.882

9.  Iridium oxide nanomonitors: clinical diagnostic devices for health monitoring systems.

Authors:  Vinu L Venkatraman; Ravikiran K Reddy; Fengyang Zhang; David Evans; Bruce Ulrich; Shalini Prasad
Journal:  Biosens Bioelectron       Date:  2009-04-01       Impact factor: 10.618

10.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.

Authors:  Hilal A Lashuel; Benjamin M Petre; Joseph Wall; Martha Simon; Richard J Nowak; Thomas Walz; Peter T Lansbury
Journal:  J Mol Biol       Date:  2002-10-04       Impact factor: 5.469

View more
  28 in total

1.  Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase.

Authors:  Marthe H R Ludtmann; Plamena R Angelova; Natalia N Ninkina; Sonia Gandhi; Vladimir L Buchman; Andrey Y Abramov
Journal:  J Neurosci       Date:  2016-10-12       Impact factor: 6.167

Review 2.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

Review 3.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

4.  The prion hypothesis of Parkinson's disease.

Authors:  Yaping Chu; Jeffrey H Kordower
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

Review 5.  Unbiased approaches to biomarker discovery in neurodegenerative diseases.

Authors:  Alice S Chen-Plotkin
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

Review 6.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

7.  Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples.

Authors:  Srinath Kasturirangan; Tim Reasoner; Philip Schulz; Shanta Boddapati; Sharareh Emadi; Jon Valla; Michael R Sierks
Journal:  Biotechnol Prog       Date:  2013-03-07

8.  Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Authors:  Stephanie M Williams; Philip Schulz; Michael R Sierks
Journal:  Eur J Neurosci       Date:  2015-10-15       Impact factor: 3.386

Review 9.  Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases.

Authors:  Claudio Soto; Sandra Pritzkow
Journal:  Nat Neurosci       Date:  2018-09-24       Impact factor: 24.884

10.  Neonatal exposure to lipopolysaccharide enhances accumulation of α-synuclein aggregation and dopamine transporter protein expression in the substantia nigra in responses to rotenone challenge in later life.

Authors:  Lu-Tai Tien; Asuka Kaizaki; Yi Pang; Zhengwei Cai; Abhay J Bhatt; Lir-Wan Fan
Journal:  Toxicology       Date:  2013-04-05       Impact factor: 4.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.